-

Citi Appointed as Depositary Bank for Molecular Partners AG’s ADR Programme

LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Molecular Partners AG (“Molecular Partners”), a clinical-stage biotech company, to act as depositary bank for its American Depositary Receipt (“ADR”) programme.

Molecular Partners’ American Depositary Shares (“ADS”) trade on the Nasdaq Global Market under the symbol “MOLN”. Each ADS represents one ordinary share of the company.

Andreas Emmenegger, Molecular Partners’ CFO, said: “We are pleased to be working with Citi as part of the team supporting our new Nasdaq listing.”

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Molecular Partners’ ADR programme and expanding the company’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, please visit www.citi.com/dr

About Molecular Partners

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi

Contacts

Citi Media Contacts:
Shani Halstead
+44 (0) 20 7508 2352
shani.halstead@citi.com

Molecular Partners Investor Contact:
Seth Lewis
+1 781 420 2361
seth.lewis@molecularpartners.com

Industry:

Citi

NYSE:C
Release Versions
English

Contacts

Citi Media Contacts:
Shani Halstead
+44 (0) 20 7508 2352
shani.halstead@citi.com

Molecular Partners Investor Contact:
Seth Lewis
+1 781 420 2361
seth.lewis@molecularpartners.com

More News From Citi

Citi Advances Real-Time Asset Servicing Globally with Single Event Processing

LONDON--(BUSINESS WIRE)--Citi Investor Services, which delivers the bank’s leading and comprehensive post-trade platform, has marked a significant step in its advancement of real-time asset servicing with the launch of its Single Event Processing (SEP) technology. The bank expects the majority of its custody flows to be processed using SEP by 2026. SEP unifies Citi’s global and direct custody infrastructure so that every asset servicing transaction will be processed in real-time through a singl...

Citi Whitepaper: Global Post-Trade Industry Poised for Further Transformation Driven by Digital Assets, Accelerated Settlements and the Adoption of AI

LONDON--(BUSINESS WIRE)--Citi’s latest “Securities Services Evolution” whitepaper details how the global post-trade industry is poised for further transformation in speed, resilience and the cost of trade processing. Following years of groundwork, market participants are now focused on execution, and the delivery of initiatives to drive heightened efficiencies and innovation. Citi’s fifth and latest edition of the annual whitepaper polled 537 industry leaders – the largest participation so far...

Citi Appointed as Depositary Bank for Nightingale Health OYJ’s ADR Program

LONDON--(BUSINESS WIRE)--Citi Issuer Services, acting through Citibank N.A., has been appointed by Nightingale Health OYJ (“Nightingale Health”) to act as depositary bank for its sponsored Level 1 American Depositary Receipt (“ADR”) program. Nightingale Health’s ADRs are traded on the OTCQX platform under the symbol “NHLTY”. Each ADR represents one ordinary share of the company. Nightingale Health’s underlying ordinary shares are listed and traded on the Nasdaq Helsinki Stock Exchange under the...
Back to Newsroom